impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Review

 

Gout: one year in review 2026

1, 2, 3, 4, 5, 6, 7, 8, 9

 

  1. Centre for Gout & Metabolic Bone and Joint Diseases, Rheumatology, Ospedale Civile S.S. Giovanni e Paolo, Venice, Italy. punzileonardo@gmail.com
  2. Rheumatology Unit, Department of Medicine (DIMED), Padova University Hospital, Italy.
  3. Laboratory Medicine Unit, Departement of Medicine (DIMED), Padova University Hospital, Italy.
  4. Rheumatology Unit, Department of Medicine (DIMED), Padova University Hospital, Italy.
  5. Rheumatology Unit, Department of Medicine (DIMED), Padova University Hospital, Italy.
  6. Rheumatology Unit, Department of Medicine (DIMED), Padova University Hospital, Italy.
  7. Rheumatology Unit, Department of Medicine (DIMED), Padova University Hospital, Italy.
  8. Rheumatology Unit, Department of Medicine (DIMED), Padova University Hospital, Italy.
  9. Rheumatology Unit, Department of Medicine (DIMED), and Department of Surgery, Oncology and Gastroenterology (DiSCOG), Padova University Hospital, Italy. roberta.ramonda@unipd.it

CER19796
Review

Free to view
(click on article PDF icon to read the article)

PMID: 42024560 [PubMed]

Received: 11/02/2026
Accepted : 01/04/2026
In Press: 09/04/2026

Abstract

The year 2025 marked a significant evolution in the understanding and management of gout, characterised by a growing focus on personalised medicine and multidimensional pathogenetic models. This review provides a comprehensive analysis of the scientific literature published during 2025, highlighting key advancements across several fields. Specifically, we discuss emerging epidemiological trends, such as the rising incidence of early-onset gout, and the integration of artificial intelligence into diagnostic imaging. Groundbreaking genetic studies are explored, identifying early-onset disease as a potentially distinct subset, alongside new insights into the ‘gut-kidney axis’ and the role of the microbiome in urate homeostasis. Furthermore, this review examines updated pathogenetic mechanisms involving immunometabolic reprogramming and evaluates the latest therapeutic strategies for both gouty arthritis and asymptomatic hyperuricaemia.

DOI: https://doi.org/10.55563/clinexprheumatol/9xhnbu

Rheumatology Article